Prelude Therapeutics Inc
About Prelude Therapeutics Inc
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $12.1M
- Net income
- -$99.5M
- Total assets
- $141.3M
- Market cap
- $303.4M
- Operating margin
- -861.3%
- Net margin
- -819.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $12.1M
- Operating expenses
- $116.7M
- Operating income
- -$104.6M
- Income tax
- $0
- Net income
- -$99.5M
- EPS (basic)
- $-1.29
- EPS (diluted)
- $-1.29
Balance sheet
- Total assets
- $141.3M
- Current assets
- $105.7M
- Total liabilities
- $72.7M
- Current liabilities
- $53.0M
- Shareholders’ equity
- $68.6M
Cash flow
- Operating cash flow
- -$56.3M
- Investing cash flow
- $53.5M
- Financing cash flow
- $24.8M
- Net cash flow
- $22.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $303.4M
- EPS (diluted)
- $-1.29
- Shares outstanding
- 76.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $99.5M in FY2025.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Prelude Therapeutics Inc.
Write a review
News about Prelude Therapeutics Inc
News & sentiment via Polygon.io
